Bioequivalence For Modified-Release Drugs Will Need Non-Replicate Studies
This article was originally published in The Tan Sheet
Executive Summary
FDA's revised bioavailability/bioequivalence guidance recommends non-replicate study designs for modified-release dosage forms
You may also be interested in...
FDA Generics Office To Revise BCS Waiver Guidance Under Science Director
FDA's Office of Generic Drugs is planning to revise the final guidance on biopharmaceutics classification system-based biowaivers under the leadership of Director for Science Lawrence Yu, PhD
FDA Generics Office To Revise BCS Waiver Guidance Under Science Director
FDA's Office of Generic Drugs is planning to revise the final guidance on biopharmaceutics classification system-based biowaivers under the leadership of Director for Science Lawrence Yu, PhD
FDA Generics Office To Revise BCS Waiver Guidance Under Science Director
FDA's Office of Generic Drugs is planning to revise the final guidance on biopharmaceutics classification system-based biowaivers under the leadership of Director for Science Lawrence Yu, PhD